Allied Market Research published a report, titled, “Atherosclerosis Drugs Market by Drug Type (Anti-platelet & Anticoagulant, Cholesterol Lowering Medication, ACE Inhibitors, and Others), by Route of Administration, (Oral, and Parenteral), and by Distribution Channel, (Hospital Pharmacies, Online Providers, and Drug Stores & Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032″. According to the report, the global atherosclerosis drugs industry generated $20.6 billion in 2022, and is anticipated to generate $27.7 billion by 2032, witnessing a CAGR of 3.0% from 2023 to 2032.
Download Sample Report: https://www.alliedmarketresearch.com/request-sample/13554
Prime determinants of growth
Surge in the obesity in the populace, increase in government initiatives to promote healthy lifestyle and development of new treatments for atherosclerosis drive the growth of the global atherosclerosis drugs market. However, the side effects of atherosclerosis drugs restricts the market growth. Moreover, high growth potential of atherosclerosis drugs in emerging markets presents new opportunities in the coming years.
Covid-19 Scenario
- The COVID-19 pandemic had a negative effect on the global atherosclerosis drugs market owing to decrease in demand for atherosclerosis drugs due to the low hospitalization rate and many surgeries either canceled or postponed due to the pandemic.
- In addition, delays in diagnosis or treatment for atherosclerosis during pandemic decreased the adoption of drugs and hampered the market growth.
- However, the market is recovering after pandemic, and experiencing a stable growth for atherosclerosis drugs market owing to increase in number of patients visits for diagnosis of atherosclerosis, continuous product approvals and clinical trials for atherosclerosis.
The anti-platelet and anticoagulants segment to maintain its leadership status throughout the forecast period
Based on drug type, the anti-platelet and anticoagulant segment held the largest market share in 2022, accounting for more than half of the global atherosclerosis drugs market revenue, and is estimated to maintain its leadership status throughout the forecast period. Rise in prevalence of atherosclerotic cardiovascular led to increase in demand for anti-platelet drugs. However, the cholesterol lowering medication segment is expected to witness the fastest CAGR of 4.2% from 2023 to 2032.Cholesterol lowering medication drugs are proven to effectively reduce the risk of atherosclerosis, which is expected to drive the growth of the segment.
The oral segment to maintain its leadership status throughout the forecast period
On the basis of route of administration, the oral segment held the largest market share in 2022, accounting for more than four-fifths of the global atherosclerosis drugs market and is estimated to maintain its leadership status throughout the forecast period. The growth is attributed to the easy availability of wide variety of oral drugs, less expensive than other drugs, and easy to administer which is expected to drive the growth of the segment. However, the injectable segment is expected to witness the fastest CAGR of 4.5% from 2023 to 2032. This is due to the fact that injectable drugs are effective in the treatment of atherosclerosis is a major factor that propels the growth of segment.
Procure Complete Report (250 Pages PDF with Insights, Charts, Tables, and Figures) @
https://www.alliedmarketresearch.com/checkout-final/cd4fad24e5cd8481539ee4d7d05e0b54
The drug stores & retail pharmacies segment to maintain its lead position during the forecast period
Based on distribution channel, the drug store & retail pharmacies segment accounted for the largest share in 2022, contributing to more than half of the global atherosclerosis drugs market revenue, and is projected to maintain its lead position during the forecast period. Easy availability of medications such in drug stores & retail pharmacies which drives the segmental growth. However, the online providers segment is estimated to showcase e the fastest CAGR of 4.1% from 2023 to 2032. The growth of segment is driven by easy availability of atherosclerosis drugs which helps patients buy products at ease and rise in usage of online apps
North America to maintain its dominance by 2032
Based on region, North America held the largest market share in terms of revenue in 2022, accounting for more than two-fifths of the global atherosclerosis drugs market revenue, and is likely to dominate the market during the forecast period. Easy availability of products for diagnosis, and higher healthcare expenditure, increase in awareness about early diagnosis of disease and higher adoption of drugs for the treatment of atherosclerosis promoted the growth of the atherosclerosis drugs market in North America. However, the Asia-Pacific region is expected to witness the fastest CAGR of 4.6% from 2023 to 2032. Rise in health awareness, increase in prevalence of atherosclerosis, and surge in awareness of preventive healthcare in the Asia-Pacific region, is expected to drive the growth of the atherosclerosis drugs market.
Leading Market Players: –
- Amgen Inc.
- Pfizer Inc.
- AstraZeneca
- Bayer AG
- Sanofi
- Novartis AG
- Viatris
- Johnson & Johnson
- Lupin
- Bausch Health Companies Inc.
The report provides a detailed analysis of these key players in the global atherosclerosis drugs market. These players have adopted strategy such product approval to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.
𝐎𝐮𝐫 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐏𝐫𝐨𝐯𝐢𝐝𝐞𝐬 𝐘𝐨𝐮 𝐀𝐧𝐬𝐰𝐞𝐫 𝐭𝐨 𝐁𝐞𝐥𝐨𝐰 𝐌𝐞𝐧𝐭𝐢𝐨𝐧𝐞𝐝 𝐐𝐮𝐞𝐬𝐭𝐢𝐨𝐧:
- Which are the driving factors responsible for the growth of market?
- Which are the roadblock factors of this market?
- What are the new opportunities, by which market will grow in coming years?
- What are the trends of this market?
- Which are main factors responsible for new product launch?
- How big is the global & regional market in terms of revenue, sales and production?
- How far will the market grow in forecast period in terms of revenue, sales and production?
- Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
- How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
- Which region has more opportunities?
𝐁𝐲 𝐑𝐞𝐠𝐢𝐨𝐧 𝐎𝐮𝐭𝐥𝐨𝐨𝐤
- North America
(U.S., Canada, Mexico)
- Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
- Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
- LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐃𝐞𝐭𝐚𝐢𝐥𝐬:
David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
𝐀𝐛𝐨𝐮𝐭 𝐔𝐬
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
